Compare Novo Nordisk A/S (NVO) vs Otis Worldwide Corp (OTIS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs Otis Worldwide Corp — how do they compare? Novo Nordisk A/S trades at $45.1 (market cap $200.69B), while Otis Worldwide Corp trades at $69.36 (market cap $26.67B). The key difference: Novo Nordisk A/S is far larger — about 7.5× Otis Worldwide Corp's market cap, and Novo Nordisk A/S pays the higher dividend (3.98%). Which is the better fit depends on your goals.
| NVO | OTIS | |
|---|---|---|
Market Cap | $200.69B | $26.67B |
Sector | Health | Industrials |
52-Week High | $63.98 | $93.62 |
52-Week Low | $35.29 | $69.30 |
Enterprise Value | $215.49B | $34.70B |
Dividend Yield | 3.98% | 2.51% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novo Nordisk (NVO) trades at $45.16, down 3.09% on the day, with a bearish technical outlook. The stock shows strong fundamentals, including a P/E of 11.07, net income margin of 35.35%, and consistent earnings beats. Recent news highlights the launch of Wegovy pill in Germany and positive pediatric obesity trial results, though competition with Eli Lilly remains intense.
The outlook is mixed: strong profitability and analyst buy consensus (57.9%) support upside, but technical weakness and competitive pressures pose risks. Revenue growth is steady, with 2026 projections at $329.4B, but recent trial halts for cardiovascular drugs dim diversification prospects.
Otis Worldwide Corporation (OTIS) trades at $70.06, down 1.61% on the day, reflecting recent bearish momentum. The stock shows mixed signals with a bearish technical trend but holds a P/E of 18.01 and net income margin of 10.17%. Recent Q2 2026 earnings beat estimates with $1.01 EPS, though full-year guidance was trimmed due to service margin pressures. Institutional activity includes new acquisitions by Caisse de depot et placement du Quebec (7,367 shares, August 31, 2026).
The outlook is cautious; analyst consensus is a Buy with a $92.50 price target, implying 32% upside, but risks include weak new equipment demand in China and rising labor costs. The stock's current price near support at $70 suggests potential stability if service growth accelerates, but investors face headwinds from margin compression and high debt levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About Otis Worldwide Corp
Otis is the largest global elevator and escalator supplier by revenue with around one quarter of share excluding Japan. In 1854 Otis' founder and namesake, Elisha Graves Otis, invented a safety mechanism that prevented elevators from falling if the hoisting cable failed.The company's product and service lifecycle begins with installations of elevator units in new buildings, later selling maintenance services on the units, and eventually replacement of the units after the average 15-20 year useful life of an elevator. As the largest global OEM, over decades Otis has built a base of 2 million elevators under service. Its business model is much the same as that of its competitors Kone, Schindler, and Thyssenkrupp.
Read more on OTIS →
